Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial

Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

Yoav Benjamini, Yosef Hochberg · Journal of the Royal Statistical Society Series B (Statistical Methodology) · 1995 · 105.5K citations

Engineering, Statistical Foundation, Powerful Approach +21

Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction

Steven M. Haffner, Seppo Lehto, Tapani Rönnemaa et al. · New England Journal of Medicine · 1998 · 7K citations · Full text

Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia

M. H. Frick, Olli Elo, Kauko Haapa et al. · New England Journal of Medicine · 1987 · 3.9K citations

Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol

Hanna E. Bloomfield, Sander J. Robins, Dorothea Collins et al. · New England Journal of Medicine · 1999 · 3.4K citations · Full text

Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events

Sander J. Robins, Dorothea Collins, Janet Wittes et al. · JAMA · 2001 · 922 citations